blenrep news - Search News

Reuters on MSN · 2d

GSK's drug combo shown to cut risk of death by 42% in type of blood cancer

British drugmaker GSK said on Monday its experimental cancer drug Blenrep in combination with other treatments reduced the risk of death by 42% in multiple myeloma, a common type of blood cancer, at or after first relapse compared to an existing treatment.

Benzinga.com · 1d

GSK's Blood Cancer Drug Shows Improved Survival Compared To Johnson & Johnson's Darzalex

GSK's Blenrep combo demonstrates significant survival benefits and improved efficacy in relapsed multiple myeloma compared to Darzalex combo.

The Wall Street Journal on MSN · 2d

GSK Gets Positive Results in Blood-Cancer Drug Trial

Blenrep, in combination with other drugs, reduced the risk of death by 42% in patients with multiple myeloma whose first treatment didn’t work or who had severe side effects.

This Is Money on MSN · 2d

Boost for GSK as new bone marrow cancer drug drastically cuts risk of death in patients

The results will be welcomed by boss Emma Walmsley (pictured), who has been trying to improve the pipeline of new drugs and vaccines.

Seeking Alpha on MSN · 2d

GSK's belantamab mafodotin reduced death risk by 42% in study

GSK (NYSE:GSK) reported that a study showed its drug belantamab mafodotin was able to reduce the risk of death by 42% in patients with multiple myeloma at or after first relapse. The study is evaluating belantamab mafodotin in combination with bortezomib plus dexamethasone,

2d

GSK’s multiple myeloma ADC Blenrep was pulled from the market. Now, it’s poised for a comeback.

GSK’s cancer drug failed a confirmatory trial two years after an accelerated approval, but impressive new survival data could ...

ASH: With survival win against J&J's Darzalex, GSK bolsters case for return of myeloma ADC Blenrep

Based on DREAMM-7 and another positive phase 3 trial, DREAMM-8 for Blenrep’s combination with Bristol Myers Squibb’s Pomalyst ...

ASH: Blenrep ups survival by 42% in multiple myeloma trial

The data reported at ASH revealed a 74% OS rate in the Blenrep plus BorDex (BVd) arm of DREAMM-7 versus a 60% rate with ...

Johnson & Johnson seeks first drug approval for treatment of smoldering myeloma

Market analysts liked the news, with analysts for Cantor writing that this was a “best-case data update.” ...

GSK highlights positive Blenrep data from Phase 3 trial at ASH

GSK announces success of their drug Blenrep at reducing the risk of death in patients diagnosed with multiple myeloma.

ENDPOINTS NEWS2d

GSK reports Blenrep overall survival data in multiple myeloma as it plots market reentry

Two years after pulling Blenrep from the market, GSK is positioning for a relaunch. This time, the company says it’s coming ...

GSK myeloma medicine improves survival in trial, another step in the drug’s revival

GSK last month announced that Blenrep had succeeded in improving overall survival in the trial, called DREAMM-7. The detailed ...

Blenrep Combo Accepted for FDA Review in R/R Multiple Myeloma

The FDA has accepted a biologics license application for Blenrep plus bortezomib or pomalidomide for patients with relapsed ...

2d

GSK announces NMPA of China accepted review of NDA for Blenrep

GSK (GSK) announced that the National Medical Products Administration, NMPA, of China has accepted for review a new drug application, NDA, for ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results